Korean J Gastroenterol.  2021 Mar;77(3):145-147. 10.4166/kjg.2021.013.

Outcome of Immune Checkpoint Inhibitor and Molecular Target Agent Combination for Advanced Hepatocellular Carcinoma: Beyond Sorafenib Era

• Nae-Yun NY

• KMID: 2514092
• DOI: http://doi.org/10.4166/kjg.2021.013

Reference

1. Finn RS, Qin S, Ikeda M, et al. 2020; Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. DOI: 10.1056/NEJMoa1915745. PMID: 32402160.

2. Llovet JM, Bustamante J, Castells A, et al. 1999; Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 29:62–67. DOI: 10.1002/hep.510290145. PMID: 9862851.

3. Yoon JS, Lee HA, Park JY, et al. 2020; Hepatocellular carcinoma in Korea between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. J Liver Cancer. 20:41–52. DOI: 10.17998/jlc.20.1.41.

4. Llovet JM, Ricci S, Mazzaferro V, et al. 2008; Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. DOI: 10.1056/NEJMoa0708857. PMID: 18650514.

5. Saffo S, Taddei TH. 2019; Systemic management for advanced hepatocellular carcinoma: a review of the molecular pathways of carcinogenesis, current and emerging therapies, and novel treatment strategies. Dig Dis Sci. 64:1016–1029. DOI: 10.1007/s10620-019-05582-x. PMID: 30887150.

6. Kudo M, Finn RS, Qin S, et al. 2018; Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. DOI: 10.1016/S0140-6736(18)30207-1. PMID: 29433850.

7. El-Khoueiry AB, Sangro B, Yau T, et al. 2017; Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389:2492–2502. DOI: 10.1016/S0140-6736(17)31046-2. PMID: 28434648. PMCID: PMC7539326.

8. Yau T, Park JW, Finn RS, et al. 2019; LBA38_PR - CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 30:v874–v875. DOI: 10.1093/annonc/mdz394.029.

9. Rini BI, Powles T, Atkins MB, et al. 2019; Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 393:2404–2415. DOI: 10.1016/S0140-6736(19)30723-8. PMID: 31079938.

10. Finn RS, Zhu AX. 2021; Evolution of systemic therapy for hepatocellular carcinoma. Hepatology. 73(Suppl 1):150–157. DOI: 10.1002/hep.31306. PMID: 32380571.